Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2022-02-04 00:00:00 ET · period of report 2022-02-02 · accession 0001567619-22-002522 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-04 | 2022-02-02 | CTMX | Campoy Carlos | CFO | A - Grant | $0.00 | +22.5K | 28.9K | +350% | $0 |
| D | 2022-02-04 | 2022-02-02 | CTMX | Campoy Carlos | CFO | A - Grant | $0.00 | +135.0K | 135.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-02 | A | A | 22,500 | $0.00 | 28,921 | D | — | — | (F1) Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on March 15 of each year, with the first 1/4th vesting on March 15, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. (F2) Includes 22,500 RSUs. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-02-02 | A | A | 135,000 | $0.00 | 135,000 | D | $4.13 · — to 2032-02-01 | 135,000 Common Stock | (F3) 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |